Clinical Trial Update: High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of high-dose gemcitabine, busulfan, and melphalan for patients with refractory Hodgkin's lymphoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Gemcitabine (Gemcitabine)
• Melphalan (Melphalan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-12-16